FMP

FMP

Enter

BDSX - Biodesix, Inc.

Financial Summary of Biodesix, Inc.(BDSX), Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The comp

photo-url-https://financialmodelingprep.com/image-stock/BDSX.png

Biodesix, Inc.

BDSX

NASDAQ

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

1.26 USD

-0.02 (-1.59%)

About

ceo

Mr. Scott Hutton

sector

Healthcare

industry

Medical - Diagnostics & Research

website

https://www.biodesix.com

exchange

NASDAQ

Description

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide trea...

CIK

0001439725

ISIN

US09075X1081

CUSIP

09075X108

Address

2970 Wilderness Place

Phone

303 417 0500

Country

US

Employee

217

IPO Date

Oct 28, 2020

Summary

CIK

0001439725

Exchange

NASDAQ

Industry

Medical - Diagnostic...

Sector

Healthcare

CUSIP

09075X108

ISIN

US09075X1081

Country

US

Price

1.26

Beta

1.12

Volume Avg.

141.38k

Market Cap

144.33M

Shares

-

52-Week

1.03-2.21

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.97

P/B

-

Website

https://www.biodesix.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest BDSX News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep